https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Exploring the economic benefits of modafinil for post-stroke fatigue in Australia: a cost-effectiveness evaluation https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47147 post hoc cost-effectiveness analysis was undertaken. Part A: patient-level cost and health effect data (Multidimensional Fatigue Inventory (MFI) scores) were derived from the MIDAS trial and analysis undertaken from a health-system perspective. Part B: a secondary analysis simulated the societal impact of modafinil therapy in terms of national productivity costs. Results: Part A: Mean cost of modafinil treatment was AUD$3.60/day/patient for a minimally clinically important change (10 points) in total MFI fatigue score, i.e., AUD$0.36/day/unit change in fatigue score per patient. For the base case scenario, the ICER of using modafinil (versus placebo) was AUD$131.73 ($90.17 - 248.15, for minimum and maximum costs, respectively). Part B: The potential productivity cost-savings to society were calculated as nearly AUD$467 million over 1 year, and up to $383,471,991,248 over 10 years, from the widespread use of modafinil treatment in the Australian population of working-age stroke-survivors, representing a significant societal benefit. Conclusions: Modafinil is a highly cost-effective treatment for post-stroke fatigue, offering significant productivity gains and potential cost-savings to society from the widespread use of modafinil treatment in the Australian population of working-age stroke-survivors.]]> Wed 14 Dec 2022 15:27:36 AEDT ]]> National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47107 Wed 14 Dec 2022 14:23:56 AEDT ]]> Contemporary approaches to managing Atrial fibrillation: a survey of Australian general practitioners https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22554 Wed 11 Apr 2018 13:42:24 AEST ]]> A cluster-randomized controlled trial of a computerized antithrombotic risk assessment tool to optimize stroke prevention in general practice: a study protocol https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16097 Tue 24 Aug 2021 14:26:09 AEST ]]> Patients' attitudes and approaches to the self-management of hypertension: perspectives from an Australian qualitative study in community pharmacy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33293 Tue 02 Oct 2018 11:57:20 AEST ]]> National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35092 Tue 01 Nov 2022 11:14:32 AEDT ]]> Healthcare Providers' Attitudes and Experiences of the Quality Use of Medications Among Culturally and Linguistically Diverse Patients in Australia: A Systematic Review of Qualitative Studies https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53992 Thu 25 Jan 2024 13:10:51 AEDT ]]> Culturally and linguistically diverse patients’ perspectives and experiences on medicines management in Australia: a systematic review https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53885 Mon 22 Jan 2024 14:21:56 AEDT ]]> Medicines use issues perceived by Arabic-speaking patients living in English-speaking countries: A systematic review https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51388 Mon 04 Sep 2023 13:13:02 AEST ]]> Rural versus metropolitan comparison of processes of care in the community-based management of TIA and minor stroke in Australia (an analysis from the INSIST study) https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50542 Fri 18 Aug 2023 12:00:25 AEST ]]>